Press Releases
Immunomic Therapeutics Inc. Expands into South Korea
Featured Highlights Press Press ReleasesSeoul Office Will Be Opening to Develop Immunomic Therapeutics Investigational Cell Therapy for Brain Cancer September 10, 2020 08:00 AM Eastern Daylight Time SEOUL--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-heldRead more- Featured Press Press ReleasesImmunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM~25-35 % survival over 5 years from diagnosis in vaccinated GBMRead more
Replicate Bioscience and ITI Form Collaboration to Combat Infectious Diseases and Cancers
Featured Press Press Releases-Immunomic to invest in Replicate’s seed round; funding will enable Replicate to accelerate self-replicating RNA technology and grow operations- June 24, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md. &Read more- Featured Press Press Releases-First-in-Human Phase I study is anticipated to commence in 2021- June 16, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneeringRead more
Immunomic Therapeutics to Present at AACR Virtual Annual Meeting II
Press Press ReleasesData from preclinical studies demonstrates that UNITE, as a nucleic acid platform, elicits potent immune responses in mice June 11, 2020 04:05 PM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics,Read moreImmunomic Therapeutics Announces Appointments to its Board of Directors
Featured Press Press Releases-ITI Board adds significant oncology drug development and commercialization expertise to the Board- May 05, 2020 08:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stageRead moreImmunomic Therapeutics Announces Close of $61.3M Financing
Featured Press Press Releases-Proceeds to support acceleration of Phase II clinical trial for GBM, advancement of pipeline, including development of COVID-19 vaccine candidate and expansion of opportunities for its UNITE nucleic acid platform-Read morePharmaJet partners with ITI and EpiVax to develop and deliver COVID-19 Vaccine
Featured Press Press ReleasesGOLDEN, Colo., April 14, 2020 /PRNewswire/ -- PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Tropis® Needle-free injection system will be used to deliver a COVID-19 vaccine beingRead more- Featured Press Press ReleasesApril 09, 2020 04:00 PM Eastern Daylight Time ROCKVILLE, Md. & PROVIDENCE, R.I. & GOLDEN, Colo.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the studyRead more
- Featured Press Press Releases- Meeting on ITI-1001 Phase I program for treatment of Newly-Diagnosed Glioblastoma (GBM) - March 03, 2020 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately heldRead more
- Featured Press Press ReleasesNov. 20, 2019 ROCKVILLE, MD – Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that Duane Mitchell, MD,Read more
Immunomic Therapeutics Announces Presentations at Upcoming Scientific and Medical Conferences
Featured Press Press ReleasesNovember 04, 2019 08:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, today announced thatRead more